Long-Term Outcome of Merkel Cell Carcinoma After Avelumab Exposure

From General Health Awareness to Occupational Exposure Concerns

The legacy of general health and science communication has long emphasized broad public awareness of disease prevention, early detection, and treatment options. Within this tradition, information about skin cancers has typically focused on sun exposure, UV protection, and routine dermatological screening. This foundational knowledge remains essential for population-level health outcomes. Transitioning from this general health context to a more specialized occupational exposure concern requires careful reframing. In mass production environments, workers may encounter chemical agents or industrial processes that introduce distinct health considerations beyond typical lifestyle risk factors. The shift in focus moves from universal prevention messages to targeted surveillance of specific exposure pathways. For individuals with occupational histories involving potential carcinogen contact, the clinical trajectory following diagnosis may differ from the general population. When considering therapeutic interventions such as immune checkpoint inhibitors, the long-term prognosis becomes particularly relevant for those whose disease etiology may be linked to workplace conditions rather than conventional risk profiles. This occupational lens reframes the discussion from broad health guidance to a more precise evaluation of exposure-related outcomes, without altering established clinical management principles.

Avelumab as a Targeted Therapy for Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The clinical presentation of MCC typically involves a rapidly growing, painless, firm skin nodule, often on sun-exposed areas such as the head, neck, and extremities. Diagnosis is confirmed through histopathological examination and immunohistochemical staining, which reveals neuroendocrine differentiation. MCC is associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality, particularly when it metastasizes (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Clinical Evidence and Treatment Outcomes

The approval of avelumab for metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200. In Part A of this study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibition, including with avelumab, has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, five patients with metastatic MCC refractory to avelumab were subsequently treated with combined ipilimumab plus nivolumab. Three out of five patients responded to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG further confirmed that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study noted that immune checkpoint inhibitors, including avelumab and pembrolizumab, are approved by the U.S. Food and Drug Administration for advanced MCC, but that about 50% of patients progress on such therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Context and Adverse Events

Avelumab, like other checkpoint inhibitors, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia due to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab. The hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while irAEs can occur, they may be manageable without necessitating discontinuation of treatment. Regarding risk anchors, the adequacy of warnings about avelumab and MCC is reflected in the drug's approved labeling and the clinical trial data that support its use. The JAVELIN Merkel 200 trial provided evidence of efficacy, but also highlighted that not all patients respond, and that progression can occur (https://pubmed.ncbi.nlm.nih.gov/29799096/). Prognosis-related considerations for affected patients include the fact that MCC is aggressive and has a poor prognosis, but that avelumab offers a treatment option with durable responses in some patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The timeline between avelumab exposure and documented harm is variable; immune-related adverse events can occur during treatment, as seen in the sarcoidosis case, while progression of MCC may occur despite therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/; https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory, alternative treatments such as ipilimumab plus nivolumab may be considered, though data are limited to small studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work for Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) and works by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells.

What is the long-term prognosis for Merkel cell carcinoma after avelumab exposure?

The long-term prognosis for MCC after avelumab exposure varies. While avelumab can induce durable responses in some patients, approximately 50% of patients with advanced MCC progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who become refractory, alternative treatments such as ipilimumab plus nivolumab may be considered, though data are limited (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.